SEHK:1952Biotechs
Everest Medicines (SEHK:1952) Loss Narrows To C¥249.8m Challenging Bearish Narratives
Everest Medicines (SEHK:1952) has reported its FY 2025 first half results with revenue of C¥446.1 million and a net loss of C¥249.8 million, translating to basic EPS of a C¥0.77 loss. The company’s revenue moved from C¥301.5 million in the first half of 2024 to C¥405.2 million in the second half of 2024, and then to C¥446.1 million in the first half of 2025. Over the same periods, net losses shifted from C¥632.4 million to C¥409.0 million and then to C¥249.8 million. Trailing twelve month...